The majority of new cancer tests coming to market are proprietary assays with the test services being provided by certified labs opened by th Read More >>

(Comment on this article at http://www.financialwire.net/2010/03/09/conference-calls-today-11-1150-a-m-est-2/)

March 9, 2010 (FinancialWire) (Inv Read More >>

Myriad Genetics, Inc. (Nasdaq:MYGN) today said data that provides further clinical validation supporting its newest molecular diagnostic pr Read More >>

Analyst Downgrades for 3/5/2010... Capital One (NYSE:COF) downgraded to Neutral from Buy at Goldman... CF Industries (NYSE:CF) initiated as Market Read More >>

Myriad Genetics, a molecular diagnostic company, has launched Prolaris, a 46-gene prognostic test which quantitatively determines the risk of recurrence in Read More >>

What:

Peter Meldrum, President and CEO of Myriad Genetics, Inc. (MYGN), will visit NASDAQ MarketSite in Times Square and preside over the Read More >>

Myriad Genetics, Inc. (Nasdaq:MYGN) today announced the launch of PROLARIS(TM), a 46-gene prognostic test which quantitatively determines t Read More >>

Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that results from a recent study at community oncology practices indicate that 41% of Read More >>

Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, President and CEO, is scheduled to present at the Cowen and Com Read More >>

SmarTrend identified a Downtrend for Myriad Genetics (NASDAQ:MYGN) on January 25, 2010 at $22.70. In approximately 4 weeks, Myriad Genetics has r Read More >>

Myriad Genetics, Inc. (Nasdaq:MYGN) today said it will host an Investor Day from 11:00 a.m. to 2:00 p.m. Eastern on March 3, 2010, at the Read More >>

Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, President and CEO, is scheduled to present at the RBC Capital M Read More >>

SmarTrend identified a Downtrend for Myriad Genetics (NASDAQ:MYGN) on January 25, 2010 at $22.70. In approximately 2 weeks, Myriad Genetics has r Read More >>

Myriad Genetics' profits jumped 67 percent in its fiscal second quarter, earning the biotechnology compan Read More >>

Myriad Genetics Inc. (MYGN)

Expected next earnings release:

Announcement date: 5/4/2010 - After Market

Earnings Quarter: Q3

Announc
          
            Read More
            >>
          
        

Myriad Genetics Inc. (MYGN)

Expected next earnings release:

Announcement date: 2/2/2010 - After Market

Earnings Quarter: Q2

Announc
          
            Read More
            >>
          
        

Myriad Genetics, Inc. (Nasdaq:MYGN) today reported financial results for its second fiscal quarter and the six-month period ended December Read More >>

(Comment on this article at http://www.financialwire.net/2010/02/02/conference-calls-today-4-445-p-m-est-3/)

February 2, 2010 (FinancialWire) (In Read More >>

(Comment on this article at http://www.financialwire.net/2010/01/27/myriad-study-reveals-patients-receive-incorrect-dosing/)

January 27, 2010 (Fi Read More >>

Myriad Genetics, Inc. (Nasdaq:MYGN) announced that a presentation entitled: "Extensive 5-FU Inter-Patient Pharmacokinetic Variability Read More >>

XIFIN Inc., a provider of revenue cycle management for diagnostic service providers, said that seven of the industry's 10 largest clinical labs are worki Read More >>

XIFIN Inc., the leading provider of revenue cycle management for diagnostic service providers, announced that seven of the industr Read More >>

Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that the Company is scheduled to give a presentation entitled: "Extensive 5-FU Inter-P Read More >>

Myriad Genetics Inc. (MYGN)

Expected next earnings release:

Announcement date: 2/2/2010 - After Market

Earnings Quarter: Q2

Announc
          
            Read More
            >>
          
        

Myriad Genetics Inc. (MYGN)

Expected next earnings release:

Announcement date: 2/2/2010 - After Market

Earnings Quarter: Q2

Announc
          
            Read More
            >>
          
        

Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will release its fiscal 2010 second quarter financial results at the close of Read More >>

Analyst Downgrades for 1/12/2010... Alcoa (NYSE:AA) downgraded to Underperform from Market Perform, $15 target, at BMO Capital... Ameri Read More >>

HealthSTAR's LehmanMillet, the leading agency devoted to working with health care companies changing standards of care, today announced the add Read More >>

(Comment on this article at http://www.financialwire.net/2010/01/08/myriad-genetics-partners-with-mammography-reporting-systems/)

January 8, 2010 Read More >>

Myriad Genetics, a molecular diagnostic company, has entered into an agreement with Mammography Reporting System, or MRS, a provider of breast procedure inf Read More >>

Myriad Genetics, Inc. (Nasdaq:MYGN) announced today it has entered into an agreement with Mammography Reporting System, Inc. (MRS) to help Read More >>

Myriad Genetics Inc. (MYGN)

Expected next earnings release:

Announcement date: 2/2/2010 - Before Market

Earnings Quarter: Q2

Announ
          
            Read More
            >>